Tuesday, October 2, 2012

EASD - Insulin Degludec cuts night-time hypoglycemia rate by 43%, when compared to Insulin Glargine (Lantus)

In a 2-year (1 year initial and 1 year extension) phase 3a study, comparing the efficacy and safety of once-daily insulin degludec versus once-daily insulin glargine (both in combination with OADs), the rates
of overall hypoglycaemia were similar between the two groups (1.72 [insulin degludec] versus 2.05 [insulin glargine] episodes per patient per year, p=NS). In terms of night time hypoglycemia insulin degludec was much better. Insulin degludec was associated with a 43% lower rate of hypoglycemia compared to Lantus with equivalent improvement in glucose control.

The rates of severe hypoglycemia although were infrequent, but were significantly lower with insulin degludec compared with insulin glargine (0.01 [insulin degludec] versus 0.02 [insulin glargine] episodes per patient per year, p=0.02).

In a separate, prospectively planned meta-analysis also presented at EASD, patient level data from 4,330 patients in seven randomized, open-label, treat-to-target phase 3a trials of 26 or 52 weeks showed that insulin degludec significantly reduced the rate of night-time hypoglycemia in adults with type 1 and type 2 diabetes, while obtaining equivalent improvements in glucose control, when compared with insulin glargine

Patients with type 2 diabetes who had not previously been treated with insulin showed the greatest reductions in night-time hypoglycaemia when using insulin degludec compared with insulin glargine:
  1. 36% (p<0 .05=".05" 0.2="0.2" 0.3="0.3" 0.4="0.4" 0.8="0.8" 1.2="1.2" 3579="3579" 3586="3586" 3672="3672" and="and" compared="compared" degludec="degludec" episodes="episodes" for="for" glargine="glargine" hypoglycaemia="hypoglycaemia" ideg="ideg" iglar="iglar" in="in" insulin="insulin" li="li" night-time="night-time" patient="patient" per="per" reduction="reduction" respectively="respectively" the="the" trials="trials" versus="versus" with="with" year="year">
  2. 17% (p<0 .05=".05" 1.2="1.2" 1.4="1.4" 1.8="1.8" 2.="2." 3.0="3.0" 3.7="3.7" 3579="3579" 3586="3586" 3672="3672" and="and" compared="compared" degludec="degludec" episodes="episodes" for="for" glargine="glargine" hypoglycaemia="hypoglycaemia" ideg="ideg" iglar="iglar" in="in" insulin="insulin" li="li" overall="overall" patient="patient" per="per" reduction="reduction" respectively="respectively" the="the" trials="trials" versus="versus" with="with" year="year">
  3. 86% (p<0 .05=".05" 0.01="0.01" 0.02="0.02" 0="0" 3579="3579" 3586="3586" 3672="3672" and="and" compared="compared" degludec="degludec" episodes="episodes" for="for" glargine="glargine" hypoglycaemia="hypoglycaemia" ideg="ideg" iglar="iglar" in="in" insulin="insulin" li="li" of="of" patient="patient" per="per" rates="rates" reduction="reduction" respectively="respectively" severe="severe" the="the" trials="trials" versus="versus" with="with" year="year">